EoCene Ltd. (EOCN)
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Eocene Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 2.38 | 2.46 | 2.36 | 2.46 | 10,161 |
| Nov 16, 2026 | 2.48 | 2.54 | 2.21 | 2.53 | 7,589 |
| Nov 13, 2026 | 2.32 | 2.48 | 2.32 | 2.48 | 731 |
| Nov 12, 2026 | 2.39 | 2.51 | 2.27 | 2.39 | 3,431 |
| Nov 11, 2026 | 2.57 | 2.57 | 2.05 | 2.48 | 29,708 |
| Nov 10, 2026 | 2.48 | 2.79 | 2.48 | 2.70 | 3,863 |
| Nov 9, 2026 | 2.98 | 2.98 | 2.51 | 2.75 | 3,395 |
| Nov 6, 2026 | 2.45 | 2.74 | 2.45 | 2.74 | 3,714 |
| Nov 5, 2026 | 2.65 | 2.67 | 2.30 | 2.45 | 16,421 |
| Nov 4, 2026 | 2.77 | 2.81 | 2.77 | 2.77 | 1,142 |
| Nov 3, 2026 | 2.91 | 3.00 | 2.69 | 2.81 | 13,725 |
| Nov 2, 2026 | 3.09 | 3.09 | 2.75 | 2.87 | 9,810 |
| Oct 30, 2026 | 3.08 | 3.39 | 3.07 | 3.10 | 3,114 |
| Oct 29, 2026 | 3.17 | 3.48 | 3.17 | 3.22 | 6,759 |
| Oct 28, 2026 | 3.09 | 3.31 | 3.00 | 3.20 | 7,384 |
| Oct 27, 2026 | 3.06 | 3.19 | 3.06 | 3.08 | 2,092 |
| Oct 26, 2026 | 3.10 | 3.28 | 3.10 | 3.15 | 3,578 |
| Oct 23, 2026 | 3.11 | 3.27 | 2.96 | 3.03 | 8,768 |
| Oct 22, 2026 | 3.04 | 3.10 | 2.96 | 3.08 | 7,146 |
| Oct 21, 2026 | 2.97 | 3.12 | 2.90 | 3.12 | 7,059 |
| Name | Shares | % | Source |
|---|---|---|---|
CVI Investments, Inc. · may incl. warrants· filed Nov 2025 | 21.7K | 2.0% | 13G |
CITADEL ADVISORS LLC | 15.1K | 1.4% | 13F |
Allen Baharaff · may incl. warrants· filed Feb 2025 | 5.5K | 0.5% | 13G |
Cohen Doron Leib Chief Financial Officer | 3.1K | 0.3% | FORM 4 |
Nehemya Guy Chief Operating Officer | 3.1K | 0.3% | FORM 4 |
Stenzler Yohai Chief Accounting Officer | 3.1K | 0.3% | FORM 4 |
Nir Shmuel Director | 1.6K | 0.1% | FORM 4 |
Poshinski Amir Director | 1.6K | 0.1% | FORM 4 |
SIDRANSKY DAVID Director | 1.6K | 0.1% | FORM 4 |
ROYAL BANK OF CANADA | 69 | 0.0% | 13F |
Insiders
- Cohen Doron LeibChief Financial Officer
- Nehemya GuyChief Operating Officer
- Stenzler YohaiChief Accounting Officer
- Nir ShmuelDirector
- Poshinski AmirDirector
- SIDRANSKY DAVIDDirector
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH).
Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
based on 1.07M shares outstanding
30d Avg
7.46K
60d Avg
7.58K
90d Avg
12.51K
Signal8's dilution snapshot of EOCN as of Dec 31, 2025 records an effective F-3 shelf registration (effective Nov 21, 2024) and 1 outstanding warrant series, from SEC filings. EoCene Ltd. (NASDAQ: EOCN) traded at $2.46 on Nov 17, 2026, down 2.77% from the previous close of $2.53. The company is in the Healthcare sector (Medical - Pharmaceuticals).